Untitled case

I'll research this case using the patent numbers, NDA, and party name.

Confirmed the docket: 1:14-cv-01444 (D. Del.), filed 2014-12-01, terminated 2016-05-09. Let me identify the parties and details.

Now let me verify the docket history (stay, settlement) and PTAB linkage.

Case Overview — Helsinn Healthcare S.A. et al. v. Exela Pharma Sciences LLC et al., No. 1:14-cv-01444 (D. Del.)

Parties. The plaintiffs were Helsinn Healthcare S.A., the Swiss specialty-pharma company (Lugano-Pazzallo) that holds NDA No. 021372 and markets the branded antiemetic Aloxi® (palonosetron hydrochloride injection), together with Roche Palo Alto LLC, which appears as a co-plaintiff because the Orange Book–listed formulation patents are jointly owned (Helsinn acquired the palonosetron development/marketing rights from Roche in the late 1990s, with Roche retaining co-ownership of the later formulation IP). Helsinn was represented by Jack B. Blumenfeld and Maryellen Noreika of Morris, Nichols, Arsht & Tunnell. The defendants were Exela Pharma Sciences, LLC (the NDA sponsor, Lenoir, NC), together with affiliates Exela PharmSci, Inc. and Exela Holdings, Inc., represented by Adam Wyatt Poff and Monte Terrell Squire of Young Conaway Stargatt & Taylor. Neither side is an NPE or university — this is a classic brand-vs.-generic (Hatch-Waxman) formulation dispute. (Party/counsel details from the FJC IDB record via CourtListener docket 4220723 and the UniCourt docket summary; counsel attribution is docket-derived and not independently press-verified.)

Accused product and patents. The trigger was Exela's NDA No. 207963, filed under § 505(b)(2) — not an ANDA — seeking approval of a higher-concentration palonosetron HCl injection, 0.25 mg base/2 mL (0.125 mg/mL), versus Aloxi's 0.25 mg/5 mL (0.05 mg/mL), and notably formulated without EDTA, mannitol, or buffer (FDA NDA 207963 Summary Review / CDTL memo, accessdata.fda.gov; D.N.J. Dismissal Order, Helsinn v. Fresenius Kabi, 3:15-cv-07378, D.I. 55). That is a deliberately "lean" reformulation — a design-around aimed at the excipient limitations of the Aloxi patent wall. The two patents at issue here are from the same palonosetron formulation family: U.S. 8,518,981 (issued Aug. 27, 2013; inventors Calderari, Bonadeo, Cannella, Miksztal, Malefyt, Lee), which claims a method of manufacturing and terminally sterilizing a finished single-unit-dose vial of palonosetron (fill → seal → terminal sterilization, with the solution at pH ~4.0–6.0 and 0.03–0.2 mg/mL, optional mannitol/chelator/citrate); and U.S. 8,598,218 (issued Dec. 3, 2013), the formulation/composition counterpart covering shelf-stable aqueous palonosetron solutions useful for IV and oral liquids. Analytically

I'll research this Hatch-Waxman case, starting with the patents, parties, and docket.

Found the case: Helsinn Healthcare S.A. v. Exela Pharma Sciences, LLC, D. Del. No. 1:14-cv-01444-GMS. Let me pull the docket and related filings.

Let me pull the full docket from CourtListener and check for any motions or IPR activity.

Plaintiff side — who sued

The plaintiffs were Helsinn Healthcare S.A. (Switzerland) and Roche Palo Alto LLC (co-plaintiff/licensee; Helsinn's Aloxi® palonosetron franchise was originally developed with Roche Palo Alto). Complaint filed Dec. 1, 2014, D. Del. No. 1:14-cv-01444-GMS (Judge Gregory M. Sleet), asserting the '981 and '218 patents against Exela's 505(b)(2) NDA No. 207963; stipulated dismissal (D.I. 27) so-ordered May 9, 2016 (D.I. 28); case closed same day (D.I. 29).

Counsel of record on the D. Del. docket

These two are the only plaintiff-side attorneys extracted from the 14-1444 docket in the FJC/UniCourt attorney records (both "Designation Retained"). That pattern — local Delaware counsel only — is consistent with this case having been stayed early in favor of the parallel New Jersey palonosetron litigation (the later D.N.J. complaint describes 14-1444 as "currently stayed"), so merits counsel never needed to perfect pro hac vice admission in Delaware.

Lead / merits counsel (from the companion Helsinn matters — not confirmed as of record in 14-1444)

The same plaintiff team litigated the companion Helsinn palonosetron cases (D.N.J. 15-7378 against Fresenius/Exela; D.N.J. 11-3962, 12-2867, 13-5815, 14-4274 against Teva, Dr. Reddy's, Sandoz, etc.), and those filings identify:

• Joseph M. O'Malley, Jr. — lead trial counsel, Paul Hastings LLP, 200 Park Avenue, New York, NY (of counsel). First-chair in the Helsinn ANDA/505(b)(2) palonosetron trials (Helsinn v. Dr. Reddy's, D.N.J. 11-3962) and Helsinn's counsel through Helsinn v. Teva (Fed. Cir. 2017; Supreme Court 2019 on the AIA on-sale bar).
• Eric W. Dittmann — Paul Hastings LLP, New York (of counsel); member of the Helsinn palonosetron trial/appellate team.
• Isaac S. Ashkenazi — Paul Hastings LLP, New York (of counsel); same team.
• (Same firm/team roster in the D.N.J. filings also lists Young J. Park, Gary Ji, Angela C. Ni, and Dana Weir of Paul Hastings.)
• Mark E. Waddell — Loeb & Loeb LLP, 345 Park Avenue, New York, NY — of counsel listed for Roche Palo Alto LLC in the companion Helsinn pleadings (Roche is the co-plaintiff whose interest he would have covered).
• Charles M. Lizza and William C. Baton, Saul Ewing LLP, Newark, NJ — local counsel in the New Jersey companion actions only; they have no role in the Delaware case.

Sourcing caveats

• I could not retrieve the full 14-1444 docket sheet or PACER images; the attorney-of-record list above comes from the FJC-derived docket data mirrored on UniCourt, and the complaint/dismissal facts from CourtListener docket entries 27–29 and the FDA approval letter for NDA 207963 (which recites "Case 1:14-cv-01444-GMS" and the two patents).
• Nothing in the available record suggests any plaintiff-side filing was sealed or that counsel appeared under seal; the limitation is simply that pro hac vice papers (if any) for Paul Hastings/Loeb & Loeb in Delaware are not visible in the sources I could reach, so I have flagged O'Malley/Dittmann/Ashkenazi/Waddell as merits counsel on the companion cases rather than certifying them as of record in 14-1444. If you need the certified Delaware appearance list, pull the 14-1444 docket report from PACER (or the D.I. 1 complaint signature block) to confirm.

I'll research this case, starting with identifying the caption and parties, then locating the docket and counsel.

The metadata matches D. Del. No. 1:14-cv-01444 (Helsinn v. Exela). Let me pull that docket and Exela's filings.